Colorectal cancer and dysplasia in inflammatory bowel disease.

Fecal lipocalin 2, a sensitive and broadly dynamic non-invasive biomarker for intestinal inflammation. PLoS One (2012) 1.90

Colorectal cancer in inflammatory bowel disease: what is the real magnitude of the risk? World J Gastroenterol (2012) 1.63

VEGF receptor signaling links inflammation and tumorigenesis in colitis-associated cancer. J Exp Med (2010) 1.45

Current management of inflammatory bowel disease and colorectal cancer. Gastrointest Cancer Res (2011) 1.21

Mechanisms of intestinal inflammation and development of associated cancers: lessons learned from mouse models. Mutat Res (2010) 1.06

Potential of soluble CD26 as a serum marker for colorectal cancer detection. World J Clin Oncol (2011) 1.04

Lineage-specific T-cell responses to cancer mucosa antigen oppose systemic metastases without mucosal inflammatory disease. Cancer Res (2009) 1.01

Dysplasia-carcinoma transition specific transcripts in colonic biopsy samples. PLoS One (2012) 1.01

Caught in the Akt: regulation of Wnt signaling in the intestine. Gastroenterology (2010) 0.99

Protein expression analysis of inflammation-related colon carcinogenesis. J Carcinog (2009) 0.98

Timing of surgery in Crohn's disease: a key issue in the management. World J Gastroenterol (2008) 0.98

Serum CD26 is related to histopathological polyp traits and behaves as a marker for colorectal cancer and advanced adenomas. BMC Cancer (2010) 0.95

State-of-the-art of irritable bowel syndrome and inflammatory bowel disease research in 2008. World J Gastroenterol (2008) 0.94

Inflammatory Bowel Disease-related Colorectal Cancer in the Asia-Pacific Region: Past, Present, and Future. Intest Res (2014) 0.93

Update on inflammatory bowel disease in patients with primary sclerosing cholangitis. World J Hepatol (2014) 0.88

CD133, OCT4, and NANOG in ulcerative colitis-associated colorectal cancer. Oncol Lett (2011) 0.88

Overexpression of translocator protein in inflammatory bowel disease: potential diagnostic and treatment value. Inflamm Bowel Dis (2010) 0.85

Dynamic changes of peritoneal macrophages and subpopulations during ulcerative colitis to metastasis of colorectal carcinoma in a mouse model. Inflamm Res (2013) 0.81

Dietary modulation of inflammation-induced colorectal cancer through PPARγ. PPAR Res (2009) 0.80

Dynamic changes and functions of macrophages and M1/M2 subpopulations during ulcerative colitis-associated carcinogenesis in an AOM/DSS mouse model. Mol Med Rep (2014) 0.80

Optimizing management of Crohn's disease within a project management framework: results of a pilot study. Inflamm Bowel Dis (2011) 0.80

Circulating Serum miRNAs as Diagnostic Markers for Colorectal Cancer. PLoS One (2016) 0.80

Allicin alleviates inflammation of trinitrobenzenesulfonic acid-induced rats and suppresses P38 and JNK pathways in Caco-2 cells. Mediators Inflamm (2015) 0.79

Preclinical cancer chemoprevention studies using animal model of inflammation-associated colorectal carcinogenesis. Cancers (Basel) (2012) 0.78

Microarray analysis of differentially-expressed genes and linker genes associated with the molecular mechanism of colorectal cancer. Oncol Lett (2016) 0.78

Mechanisms of Immune Signaling in Colitis-Associated Cancer. Cell Mol Gastroenterol Hepatol (2014) 0.77

Effects of the probiotic Lactobacillus animalis in murine Mycobacterium avium subspecies paratuberculosis infection. BMC Microbiol (2013) 0.77

Translocator Protein-Mediated Stabilization of Mitochondrial Architecture during Inflammation Stress in Colonic Cells. PLoS One (2016) 0.77

Water enema multidetector CT technique and imaging of diverticulitis and chronic inflammatory bowel diseases. Insights Imaging (2013) 0.75

Regulatory T cells in colorectal cancer: from biology to prognostic relevance. Cancers (Basel) (2011) 0.75

Advanced endoscopic imaging for surveillance for dysplasia and colorectal cancer in inflammatory bowel disease: could the pathologist be further helped? Saudi J Gastroenterol (2014) 0.75

Oral administration of the anti-proliferative substance taurolidine has no impact on dextran sulfate sodium induced colitis-associated carcinogenesis in mice. J Carcinog (2010) 0.75

The roles of signal transducer and activator of transcription factor 3 in tumor angiogenesis. Oncotarget (2017) 0.75

Colorectal cancer screening and surveillance: clinical guidelines and rationale-Update based on new evidence. Gastroenterology (2003) 14.67

The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut (2001) 10.07

Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. Hum Pathol (1983) 8.24

Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med (1990) 6.87

Methylene blue-aided chromoendoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcerative colitis. Gastroenterology (2003) 5.11

Progression of flat low-grade dysplasia to advanced neoplasia in patients with ulcerative colitis. Gastroenterology (2003) 4.64

Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer (2001) 4.61

Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology (2004) 4.45

Diagnosis of colorectal tumorous lesions by magnifying endoscopy. Gastrointest Endosc (1996) 4.33

Guidelines for the management of inflammatory bowel disease in adults. Gut (2004) 4.15

Chromoscopy-guided endomicroscopy increases the diagnostic yield of intraepithelial neoplasia in ulcerative colitis. Gastroenterology (2007) 4.09

Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol (2004) 3.63

Factors affecting the outcome of endoscopic surveillance for cancer in ulcerative colitis. Gastroenterology (1994) 3.44

Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology (2007) 3.39

Are we telling patients the truth about surveillance colonoscopy in ulcerative colitis? Lancet (1994) 3.22

Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology (2003) 3.22

Cancer risk and life expectancy of children with ulcerative colitis. N Engl J Med (1971) 3.10

Consensus conference: Colorectal cancer screening and surveillance in inflammatory bowel disease. Inflamm Bowel Dis (2005) 3.01

Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol (2005) 2.98

Pancolonic indigo carmine dye spraying for the detection of dysplasia in ulcerative colitis. Gut (2004) 2.92

Risk of intestinal cancer in inflammatory bowel disease: a population-based study from olmsted county, Minnesota. Gastroenterology (2006) 2.87

Are dysplasia and colorectal cancer endoscopically visible in patients with ulcerative colitis? Gastrointest Endosc (2007) 2.76

Dysplasia-associated lesion or mass (DALM) detected by colonoscopy in long-standing ulcerative colitis: an indication for colectomy. Gastroenterology (1981) 2.75

Physicians' perceptions of dysplasia and approaches to surveillance colonoscopy in ulcerative colitis. Am J Gastroenterol (1995) 2.73

Thirty-year analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis. Gastroenterology (2006) 2.63

Increased risk of large-bowel cancer in Crohn's disease with colonic involvement. Lancet (1990) 2.58

DNA aneuploidy in colonic biopsies predicts future development of dysplasia in ulcerative colitis. Gastroenterology (1992) 2.48

How gastroenterologists screen for colonic cancer in ulcerative colitis: an analysis of performance. Gastrointest Endosc (2000) 2.42

Malignancy in Crohn's disease. Gut (1980) 2.33

Most dysplasia in ulcerative colitis is visible at colonoscopy. Gastrointest Endosc (2004) 2.27

Colorectal cancer prevention in ulcerative colitis: a case-control study. Aliment Pharmacol Ther (2000) 2.25

Diagnosis and management of dysplasia in patients with inflammatory bowel diseases. Gastroenterology (2004) 2.23

Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Ann Intern Med (2001) 2.22

Guidelines for screening and surveillance of asymptomatic colorectal cancer in patients with inflammatory bowel disease. Gut (2002) 2.13

Meta-analysis: colorectal and small bowel cancer risk in patients with Crohn's disease. Aliment Pharmacol Ther (2006) 2.12

Ulcerative colitis and Crohn's disease: a comparison of the colorectal cancer risk in extensive colitis. Gut (1994) 2.12

Backwash ileitis is strongly associated with colorectal carcinoma in ulcerative colitis. Gastroenterology (2001) 1.97

Indigo carmine-assisted high-magnification chromoscopic colonoscopy for the detection and characterisation of intraepithelial neoplasia in ulcerative colitis: a prospective evaluation. Endoscopy (2005) 1.95

Increased risk of intestinal cancer in Crohn's disease: a meta-analysis of population-based cohort studies. Am J Gastroenterol (2005) 1.95

Long-term follow-up after polypectomy treatment for adenoma-like dysplastic lesions in ulcerative colitis. Clin Gastroenterol Hepatol (2004) 1.92

A comparison of cancer risk in Crohn's disease and ulcerative colitis. Cancer (1981) 1.83

Similarity of colorectal cancer in Crohn's disease and ulcerative colitis: implications for carcinogenesis and prevention. Gut (1994) 1.75

Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gastrointest Endosc (2002) 1.65

Family history as a risk factor for colorectal cancer in inflammatory bowel disease. Gastroenterology (2001) 1.63

Long-term risk of cancer in ulcerative colitis: a population-based cohort study from Copenhagen County. Clin Gastroenterol Hepatol (2004) 1.56

Predictive and protective factors associated with colorectal cancer in ulcerative colitis: A case-control study. Gastroenterology (2006) 1.51

Cancer in Crohn's disease after diversionary surgery. A report of seven carcinomas occurring in excluded bowel. Am J Surg (1978) 1.44

Risk factors for ulcerative colitis-associated colorectal cancer in a Hungarian cohort of patients with ulcerative colitis: results of a population-based study. Inflamm Bowel Dis (2006) 1.31

Molecular biology of dysplasia and cancer in inflammatory bowel disease. Gastroenterol Clin North Am (2006) 1.20

Familial predisposition for colorectal cancer in chronic ulcerative colitis: a case-control study. Gastroenterology (1998) 1.10

Lower gastrointestinal malignancy in Crohn's disease. Gut (1994) 1.05

Interobserver variability in the diagnosis of ulcerative colitis-associated dysplasia by telepathology. Mod Pathol (2002) 1.01

Subclinical time span of inflammatory bowel disease in patients with primary sclerosing cholangitis. Dis Colon Rectum (1995) 0.96

Strategies for detecting colon cancer and/or dysplasia in patients with inflammatory bowel disease. Cochrane Database Syst Rev (2004) 0.96

The changing face of colorectal cancer in inflammatory bowel disease: progress at last! Gastroenterology (2006) 0.92

Malignant colorectal strictures in Crohn's disease. Am J Gastroenterol (1991) 0.92

Surveillance for cancer and dysplasia in inflammatory bowel disease. Gastroenterol Clin North Am (2006) 0.87

Prospective comparison of patient experience with colon imaging tests. Am J Med (2006) 2.42

Agile patency system eliminates risk of capsule retention in patients with known intestinal strictures who undergo capsule endoscopy. Gastrointest Endosc (2008) 2.42

Quality of care in inflammatory bowel disease: a review and discussion. Inflamm Bowel Dis (2010) 2.22

Low-dose smoking resumption in ex-smokers with refractory ulcerative colitis. J Crohns Colitis (2012) 2.00

Computerized detection of colonic polyps at CT colonography on the basis of volumetric features: pilot study. Radiology (2002) 1.93

Thromboembolic risk among Danish children and adults with inflammatory bowel diseases: a population-based nationwide study. Gut (2011) 1.70

Claudin-1 and claudin-2 expression is elevated in inflammatory bowel disease and may contribute to early neoplastic transformation. Lab Invest (2008) 1.64

Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol (2012) 1.57

Active Crohn's disease in the small bowel: evaluation by diffusion weighted imaging and quantitative dynamic contrast enhanced MR imaging. J Magn Reson Imaging (2011) 1.46

Computer-aided diagnosis scheme for detection of polyps at CT colonography. Radiographics (2002) 1.45

Quality indicators for inflammatory bowel disease: development of process and outcome measures. Inflamm Bowel Dis (2013) 1.33

Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab. Inflamm Bowel Dis (2009) 1.25

Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: patient-reported outcomes of the CHARM trial. Am J Gastroenterol (2008) 1.21

miR-143 and miR-145 are downregulated in ulcerative colitis: putative regulators of inflammation and protooncogenes. Inflamm Bowel Dis (2011) 1.20

Secondary gastrointestinal cancer in childhood cancer survivors: a cohort study. Ann Intern Med (2012) 1.20

5-Aminosalicylic acid therapy and the risk of colorectal cancer among patients with inflammatory bowel disease. Inflamm Bowel Dis (2007) 1.14

Patient perceptions of fecal microbiota transplantation for ulcerative colitis. Inflamm Bowel Dis (2013) 1.13

Fecal bacteriotherapy for ulcerative colitis: patients are ready, are we? Inflamm Bowel Dis (2011) 1.09

Infectious proctitis: when to suspect it is not inflammatory bowel disease. Dig Dis Sci (2011) 1.05

Serum adalimumab concentration and clinical remission in patients with Crohn's disease. Inflamm Bowel Dis (2013) 1.02

Assessment of the relationship between quality of sleep and disease activity in inflammatory bowel disease patients. Inflamm Bowel Dis (2013) 1.00

Natalizumab in Crohn's disease: results from a US tertiary inflammatory bowel disease center. Inflamm Bowel Dis (2013) 0.98

The challenge of compliance and persistence: focus on ulcerative colitis. J Manag Care Pharm (2008) 0.94

Surveillance of IBD Using High Definition Colonoscopes Does Not Miss Adenocarcinoma in Patients with Low-grade Dysplasia. Inflamm Bowel Dis (2016) 0.93

p53 mutations are associated with dysplasia and progression of dysplasia in patients with Crohn's disease. Dig Dis Sci (2007) 0.93

When should ulcerative colitis patients undergo colectomy for dysplasia? Mismatch between patient preferences and physician recommendations. Inflamm Bowel Dis (2010) 0.93

The changing face of colorectal cancer in inflammatory bowel disease: progress at last! Gastroenterology (2006) 0.92

Association between colorectal cancer and urologic cancers. Arch Intern Med (2008) 0.91

Outcome after surveillance of low-grade and indefinite dysplasia in patients with ulcerative colitis. Inflamm Bowel Dis (2010) 0.90

Comparison of routine and unprepped CT colonography augmented by low fiber diet and stool tagging: a pilot study. Abdom Imaging (2006) 0.89

Mucosal healing is associated with improved long-term outcome of maintenance therapy with natalizumab in Crohn's disease. Inflamm Bowel Dis (2013) 0.88

Association of colorectal cancer and prostate cancer and impact of radiation therapy. Cancer Epidemiol Biomarkers Prev (2009) 0.88

Superior mesenteric vein thrombosis after colectomy in a patient with Crohn's disease. Nat Clin Pract Gastroenterol Hepatol (2005) 0.87

Quantitative analysis of dynamic contrast enhanced MRI for assessment of bowel inflammation in Crohn's disease pilot study. Acad Radiol (2009) 0.87

Genetic testing for inflammatory bowel disease: focus group analysis of patients and family members. Genet Test Mol Biomarkers (2009) 0.86

We once were blind and now we see: is it time to treat ulcerative colitis to achieve mucosal healing? Clin Gastroenterol Hepatol (2011) 0.86

Clinical presentation and disease course of inflammatory bowel disease differs by race in a large tertiary care hospital. Dig Dis Sci (2014) 0.85

Assessment of variables associated with smoking cessation in Crohn's disease. Dig Dis Sci (2012) 0.85

Risk of post-operative complications associated with anti-TNF therapy in inflammatory bowel disease. World J Gastroenterol (2012) 0.85

What you see is not always what you get: raising the bar on clinical trial methodology in ulcerative colitis. Gastroenterology (2013) 0.84

Therapeutic Drug Monitoring of Anti-tumor Necrosis Factor Agents in Patients with Inflammatory Bowel Diseases. Inflamm Bowel Dis (2015) 0.84

Colonoscopic fecal microbiota transplant for recurrent Clostridium difficile infection in a child. Am J Gastroenterol (2012) 0.83

Safety and effectiveness of long-term allopurinol-thiopurine maintenance treatment in inflammatory bowel disease. Inflamm Bowel Dis (2013) 0.82

Long-term treatment of patients with a history of ulcerative colitis who develop gastritis and pan-enteritis after colectomy. J Clin Gastroenterol (2013) 0.82

The complexity and challenges of genetic counseling and testing for inflammatory bowel disease. J Genet Couns (2006) 0.81

Emerging issues in ulcerative colitis and ulcerative proctitis: individualizing treatment to maximize outcomes. Gastroenterol Hepatol (N Y) (2009) 0.81

Rescue therapy with cyclosporine or infliximab is not associated with an increased risk for postoperative complications in patients hospitalized for severe steroid-refractory ulcerative colitis. Inflamm Bowel Dis (2014) 0.80

Do patients with inflammatory bowel disease want genetic testing? Inflamm Bowel Dis (2006) 0.79

Medical professionalism and the doctor-patient relationship. Perspect Biol Med (2008) 0.79

Predictors of adalimumab dose escalation in patients with Crohn's disease at a tertiary referral center. Inflamm Bowel Dis (2011) 0.79

Identification of patients at increased risk for colorectal cancer in an open access endoscopy center. J Clin Gastroenterol (2008) 0.78

A rapid and accurate method to detect active small bowel gastrointestinal bleeding on video capsule endoscopy. Dig Dis Sci (2014) 0.78

Clinical scenarios in IBD: optimizing the use of conventional and biologic agents. Inflamm Bowel Dis (2010) 0.78

Total abdominal colectomy for refractory ulcerative colitis. Surgical treatment in evolution. J Gastrointest Surg (2011) 0.78

Incidence and predictors of clinical response, re-induction dose, and maintenance dose escalation with certolizumab pegol in Crohn's disease. Inflamm Bowel Dis (2014) 0.77

Clostridium Difficile Infection in Ulcerative Colitis: Can Alteration of the Gut-associated Microbiome Contribute to Pouch Failure? Inflamm Bowel Dis (2016) 0.77

Will a 5-ASA a day keep the cancer (and dysplasia) away? Am J Gastroenterol (2005) 0.77

Age of Diagnosis is Associated with Disease Presentation and Therapeutic Complications in Patients with Crohn's Disease. Inflamm Bowel Dis (2016) 0.77

Novel diagnostic and prognostic modalities in inflammatory bowel disease. Med Clin North Am (2010) 0.77

Chronic pouchitis versus recurrent Crohn's disease: a diagnostic challenge. Dig Dis Sci (2013) 0.76

Two brothers with skewed thiopurine metabolism in ulcerative colitis treated successfully with allopurinol and mercaptopurine dose reduction. Dig Dis Sci (2011) 0.76

Inflammation's role in rectal cancer following prostate radiotherapy, and emerging evidence for a protective role for balsalazide. Gastroenterology (2005) 0.76

Israel-Gaza conflict. Lancet (2009) 0.75

Reinduction with Certolizumab Pegol in Patients with Crohn's Disease Experiencing Disease Exacerbation: 7-Year Data from the PRECiSE 4 Study. Inflamm Bowel Dis (2016) 0.75

The Drivers of Discretionary Utilization: Clinical History Versus Physician Supply. Acad Med (2017) 0.75

Can we improve on the "see one, do one, teach one" paradigm in training fellows to care for patients with inflammatory bowel disease? Inflamm Bowel Dis (2015) 0.75

Zinc Deficiency is Associated with Poor Clinical Outcomes in Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis (2016) 0.75

Baseline Oral 5-ASA Use and Efficacy and Safety of Budesonide Foam in Patients with Ulcerative Proctitis and Ulcerative Proctosigmoiditis: Analysis of 2 Phase 3 Studies. Inflamm Bowel Dis (2016) 0.75

Early Transcriptomic Changes in the Ileal Pouch Provide Insight into the Molecular Pathogenesis of Pouchitis and Ulcerative Colitis. Inflamm Bowel Dis (2017) 0.75

Performance of CT colonography in clinical trials. Gastrointest Endosc Clin N Am (2010) 0.75

Risk of Cancer Recurrence Among Individuals Exposed to Antitumor Necrosis Factor Therapy: A Systematic Review and Meta-Analysis of Observational Studies. J Clin Gastroenterol (2017) 0.75

Joseph Barnett Kirsner, MD, PhD. Clin Gastroenterol Hepatol (2012) 0.75

Early Transcriptomic Changes in the Ileal Pouch Provide Insight into the Molecular Pathogenesis of Pouchitis and Ulcerative Colitis. Inflamm Bowel Dis (2017) 0.75

Fecal microbiota transplantation: an interest in IBD? Nestle Nutr Inst Workshop Ser (2014) 0.75

A diagnosis that eats at you. Gastroenterology (2013) 0.75

U.S. Patients with Ulcerative Colitis Do Not Have a Decreased Risk of Diverticulosis. Inflamm Bowel Dis (2015) 0.75

Patients with Ulcerative Colitis Are More Concerned About Complications of Their Disease than Side Effects of Medications. Inflamm Bowel Dis (2016) 0.75

In memoriam: Dr Joseph Barnett Kirsner. Gut (2012) 0.75

Joseph Barnett Kirsner, MD, PhD. Dig Dis Sci (2012) 0.75

The case: can doctors say "enough"? Camb Q Healthc Ethics (2003) 0.75

Higher Thioguanine Nucleotide Metabolite Levels are Associated With Better Long-term Outcomes in Patients With Inflammatory Bowel Diseases. J Clin Gastroenterol (2017) 0.75

Maximizing patient adherence and clinical outcomes with mesalamine in mildly-to-moderately active ulcerative colitis. Rev Gastroenterol Disord (2008) 0.75

Chromoendoscopy for colorectal cancer surveillance in patients with inflammatory bowel disease. Curr Gastroenterol Rep (2014) 0.75

Novel diagnostic and prognostic modalities in inflammatory bowel disease. Gastroenterol Clin North Am (2009) 0.75

Colonic infiltration with chronic myelomonocytic leukemia. Nat Clin Pract Gastroenterol Hepatol (2007) 0.75

miR-4728-3p Functions as a Tumor Suppressor in Ulcerative Colitis-associated Colorectal Neoplasia Through Regulation of Focal Adhesion Signaling. Inflamm Bowel Dis (2017) 0.75

Fever and right upper quadrant pain in a pregnant woman at 30 weeks' gestation. Nat Clin Pract Gastroenterol Hepatol (2004) 0.75

Describing the clinical phenotypes of Crohn's disease: lessons from the past: commentary on: the broadening conception of regional ileitis. Dig Dis Sci (2014) 0.75

Recommendations for Quality Colonoscopy Reporting for Patients with Inflammatory Bowel Disease: Results from a RAND Appropriateness Panel. Inflamm Bowel Dis (2016) 0.75

In memoriam. Inflamm Bowel Dis (2012) 0.75